Congenital adrenal hyperplasia is a group of inherited conditions affecting hormone production in the adrenal glands, small organs that sit above the kidneys. These glands normally produce essential hormones that help the body respond to stress, control blood pressure, regulate salt and water balance, and support normal growth and development. People with this condition require lifelong treatment to replace missing hormones and prevent serious complications, though the specific approach depends on the type and severity of the condition.

Finding the Right Path: How Treatment Goals Shape Daily Management

Treatment for congenital adrenal hyperplasia, often shortened to CAH, focuses on several important goals that go beyond simply taking medication each day. The main aim is to restore the balance of hormones that the body cannot produce on its own, which helps prevent life-threatening emergencies and supports healthy development throughout life. For children, this means ensuring they grow at a normal rate and go through puberty at the right time. For adults, treatment helps maintain energy levels, blood pressure control, and overall quality of life.^[1]

The treatment approach must be carefully tailored to each person’s specific situation. Someone with the severe classic form of CAH, which appears at birth or in early infancy, will need a very different treatment plan than someone with the milder nonclassic form, which might not become obvious until childhood or even adulthood. Medical professionals also consider the person’s age, the specific enzyme that is lacking, and whether they experience problems with salt balance in their body.^[2]

Beyond these immediate concerns, treatment aims to prevent long-term complications that can develop over many years. These may include problems with bone strength, difficulties with fertility, challenges with blood sugar control, and impacts on mental and emotional health. Because CAH affects people throughout their entire lives, the treatment plan must adapt as they move from infancy through childhood, adolescence, and into adulthood. Regular monitoring and adjustments help ensure that hormone levels stay as close to normal as possible without causing unwanted side effects.^[4]

Medical societies around the world have developed guidelines based on years of research and clinical experience. These guidelines help doctors provide consistent, evidence-based care. At the same time, researchers continue to explore new therapies that might offer better control of hormone levels with fewer side effects, including studies of experimental drugs and innovative approaches like gene therapy. Some of these newer treatments are currently being tested in clinical trials, which are carefully designed research studies that evaluate whether new therapies are safe and effective before they become widely available.^[6]

Standard Treatment Approaches: Replacing What the Body Cannot Make

The cornerstone of CAH treatment involves replacing the hormones that the adrenal glands cannot produce in sufficient amounts. For most people with classic CAH, this means taking glucocorticoid medications, which are substances that act like the hormone cortisol in the body. Cortisol plays a crucial role in helping the body respond to stress, illness, and injury. It also helps regulate blood sugar levels and blood pressure. Without enough cortisol, a person can develop a dangerous condition called adrenal crisis, which requires immediate emergency treatment.^[7]

The most commonly prescribed glucocorticoid for people with CAH is hydrocortisone. Doctors prefer this medication, especially for children, because it works in a way that closely mimics how the body naturally produces cortisol throughout the day. Hydrocortisone stays in the body for a relatively short time, which means people typically need to take it two or three times daily. This might seem inconvenient, but it actually helps prevent some of the side effects that can occur with longer-acting steroids. For adults and older adolescents who have completed puberty, doctors sometimes prescribe longer-acting alternatives such as prednisone or dexamethasone, but these carry a higher risk of side effects.^[8]

Many people with classic CAH also need a second type of hormone replacement called mineralocorticoid therapy. The medication used for this purpose is called fludrocortisone, and it replaces the hormone aldosterone. Aldosterone is essential for maintaining the right balance of salt and water in the body. Without it, the kidneys lose too much salt through urine, which can lead to dehydration, dangerously low blood pressure, and imbalances in blood chemistry. This condition is called salt-wasting, and it can quickly become life-threatening if not treated. Babies and young children with salt-wasting CAH also receive extra salt added to their formula or food to help maintain proper salt levels.^[8]

The duration of treatment for CAH is lifelong. Unlike some conditions that can be cured or that resolve on their own over time, CAH is a permanent genetic condition that requires ongoing medication. However, the specific doses and timing of medications often need adjustment as people grow, go through puberty, experience changes in activity level, or develop other health conditions. Regular blood tests help doctors monitor hormone levels and make sure the treatment is working properly without causing problems.^[11]

Like all medications, glucocorticoids and mineralocorticoids can cause side effects, especially if the doses are higher than the body actually needs. Glucocorticoids, when taken in excessive amounts over long periods, can lead to weight gain, thinning of the bones (called osteoporosis), increased blood pressure, higher blood sugar levels, mood changes, and difficulty sleeping. These effects happen because the medication is working throughout the entire body, not just replacing what is missing. This is why doctors aim to use the lowest dose that keeps the person healthy and prevents adrenal crisis while minimizing excess hormone exposure. Finding this balance can be challenging and requires careful monitoring and frequent adjustments.^[14]

Clinical practice guidelines from the Endocrine Society, an international organization of hormone specialists, provide detailed recommendations about how to manage CAH. These guidelines suggest that newborns and young infants should receive both glucocorticoid and mineralocorticoid replacement along with extra salt in their diet. The guidelines also recommend regular monitoring of growth, development, blood pressure, and hormone levels. For people with nonclassic CAH, treatment may not always be necessary. Some people with this milder form only need medication during certain times, such as when they experience symptoms related to excess male hormones, like excessive body hair growth or irregular menstrual periods.^[8]

Breaking New Ground: Experimental Therapies in Clinical Research

For more than seventy years, glucocorticoid replacement remained the only treatment option for controlling the overproduction of male hormones in people with CAH. However, the field has recently seen exciting developments with new drugs specifically designed to help manage the condition with potentially fewer side effects. These innovative treatments work through different mechanisms than traditional steroid replacement, offering hope for better long-term outcomes.^[9]

In December 2024, a significant milestone occurred when the United States Food and Drug Administration approved a new medication called crinecerfont (brand name Crenessity) for use in combination with glucocorticoid replacement. This drug represents the first new treatment approach for CAH in more than seven decades. Crinecerfont works as a corticotropin-releasing factor type 1 receptor antagonist, which means it blocks a specific signal in the brain that normally tells the adrenal glands to produce more hormones. By reducing this signal, the drug helps control the overproduction of male hormones without using additional steroids.^[8]

The mechanism of action of crinecerfont is quite different from traditional glucocorticoid therapy. In people with CAH, a part of the brain called the pituitary gland produces excessive amounts of a hormone called ACTH (adrenocorticotropic hormone). This ACTH constantly stimulates the adrenal glands, causing them to overproduce male hormones even though they cannot make enough cortisol. Traditional treatment uses high doses of glucocorticoids to suppress ACTH production, but this often requires taking more steroid medication than the body would naturally produce. Crinecerfont, by blocking the receptor that responds to corticotropin-releasing factor (the hormone that tells the pituitary to make ACTH), reduces androgen overproduction without adding more steroids to the system.^[9]

Clinical trials of crinecerfont have shown promising results. Studies have demonstrated that adding this medication to a person’s existing glucocorticoid therapy can effectively control male hormone levels while allowing doctors to reduce the dose of glucocorticoids. This is particularly important because it may help reduce the long-term side effects associated with higher doses of steroids, such as bone loss, metabolic problems, and disrupted sleep patterns. The medication has been approved for use in adults and children aged four years and older who have classic congenital adrenal hyperplasia.^[9]

Trial participants who received crinecerfont generally experienced improvements in their hormone profiles, with better control of excess male hormones while taking lower doses of glucocorticoids. The safety profile in the studies appeared favorable, though as with any new medication, long-term effects continue to be monitored. The trials included patients from various locations, and the medication has now become available through regular prescriptions rather than only through research studies.^[8]

Another innovative approach being explored is gene therapy for congenital adrenal hyperplasia. This cutting-edge research aims to address the root cause of CAH by delivering a working copy of the faulty gene into the body’s cells. Most cases of classic CAH result from mutations in a gene called CYP21A2, which provides instructions for making the enzyme 21-hydroxylase. In gene therapy, scientists use a specially modified virus as a delivery vehicle, called a viral vector, to carry functional copies of the CYP21A2 gene into cells. The goal is to restore the adrenal glands’ ability to produce the enzymes they need to make cortisol and aldosterone normally.^[10]

Gene therapy for CAH is currently in early-stage clinical trials. The approach involves giving a single intravenous dose of the gene therapy product, after which researchers follow participants for several years to monitor safety and effectiveness. If successful, this treatment could potentially allow people with CAH to produce their own hormones in response to their body’s natural signals, possibly reducing or even eliminating the need for daily medication. However, it is important to understand that gene therapy is still experimental and not yet available outside of clinical trials. The ultimate goal is for the treated adrenal glands to function normally, releasing appropriate amounts of hormones in response to stress, illness, and daily activities without requiring additional medication.^[10]

Other experimental approaches being studied include combination therapies that use multiple medications working through different mechanisms. Some research has investigated using glucocorticoids together with medications that slow down skeletal development in children (to help preserve adult height potential) and drugs that block the effects of excess male hormones. Additionally, researchers have explored using medications that reduce the production of another hormone called angiotensin II, which can help lower the required dose of mineralocorticoid replacement. These combination approaches are still being evaluated in research settings to determine their safety and effectiveness.^[8]

The hope with these newer therapeutic approaches is that they will create improvements in several areas of life for people with CAH. For children, better hormone control might help them achieve better adult height and go through puberty more normally. For adults, the goal is to maintain fertility, avoid long-term metabolic complications like diabetes and bone disease, and reduce cognitive effects that can result from taking high doses of glucocorticoids over many years. Research continues in medical centers around the world, including in the United States, Europe, and other regions, with studies enrolling both children and adults who meet specific eligibility criteria.^[9]

Most common treatment methods

• Glucocorticoid replacement therapy
  • Hydrocortisone is the most commonly used glucocorticoid, particularly preferred for children and infants because it acts more like the body’s natural cortisol rhythm
  • Prednisone may be used in adults and adolescents who have completed puberty as a longer-acting alternative
  • Dexamethasone is another long-acting option that may be prescribed for some adults, though it carries higher risk of side effects
  • Doses must be increased during times of illness, injury, surgery, or other physical stress to prevent adrenal crisis
  • Treatment is lifelong and requires regular monitoring through blood tests and clinical evaluation
• Mineralocorticoid replacement therapy
  • Fludrocortisone replaces the hormone aldosterone in people with salt-wasting forms of CAH
  • Helps maintain proper sodium and water balance in the body
  • Prevents dangerous salt loss through the kidneys
  • Often combined with sodium supplementation in infants and young children
  • Essential for preventing dehydration and maintaining blood pressure
• Corticotropin-releasing factor receptor antagonist
  • Crinecerfont (Crenessity) was approved by the FDA in December 2024
  • Works by blocking signals that cause adrenal glands to overproduce male hormones
  • Used in combination with glucocorticoid replacement, not as a replacement for it
  • May allow reduction in glucocorticoid doses, potentially decreasing long-term side effects
  • Approved for adults and children aged 4 years and older with classic CAH
• Gene therapy
  • Experimental approach currently being studied in clinical trials
  • Uses a viral vector to deliver functional copies of the CYP21A2 gene to cells
  • Given as a single intravenous dose with long-term follow-up monitoring
  • Aims to restore the adrenal glands’ ability to produce hormones naturally
  • Goal is to reduce or eliminate need for daily medication, though this remains investigational
• Emergency treatment protocols
  • Emergency injection kits containing hydrocortisone sodium succinate for use during severe illness or injury
  • Immediate intravenous fluids and medications for treating adrenal crisis
  • Increased oral glucocorticoid doses during illness, fever, or stress
  • Medical identification jewelry and emergency cards to alert healthcare providers
  • Education for patients and families about recognizing signs of adrenal insufficiency
• Combination approaches under investigation
  • Glucocorticoids combined with medications that slow bone maturation in children to preserve adult height
  • Addition of flutamide, an androgen blocker, to reduce effects of excess male hormones
  • Aromatase inhibitors being studied to slow skeletal development
  • Long-acting gonadotropin-releasing hormone agonists for children who develop early puberty
  • These approaches remain experimental and are being evaluated in research settings
• Supportive and monitoring care
  • Regular blood tests to measure hormone levels and adjust medication doses
  • Growth monitoring in children to ensure normal development
  • Blood pressure checks and bone density screening
  • Psychological support and counseling for managing chronic illness
  • Transition planning from pediatric to adult care during adolescence